Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


7 Items
Title  Creator  Group name  Publishing year 
In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2 du Manoir et al. EquipeCTCS 2022-07
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Ashraf et al. EquipeAT Feb 04, 2019
Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells Fonti et al. EquipeCTCS Sep 01, 2019
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis Leconet et al. EquipeCG Jun 01, 2017
The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway Laprevotte et al. EquipeCTCS Dec 26, 2017
Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure Colombo et al. EquipeMY Sep 29, 2015
Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse du Manoir et al. EquipeCTCS Mar 2014
7 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés